The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
 
Timothy Jay Price
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Merck
 
Marc Peeters
Honoraria - Amgen; Bayer; Merck; Roche Pharma AG; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Merck; Roche Pharma AG; Sanofi
Speakers' Bureau - Amgen; Bayer; Sanofi
Research Funding - Amgen; Merck; Roche Pharma AG
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Sanofi
 
Tae Won Kim
Honoraria - Bayer
Consulting or Advisory Role - Abbvie; Bayer
Research Funding - Bayer; Taiho Pharmaceutical
 
Jin Li
Research Funding - Merck
 
Stefano Cascinu
No Relationships to Disclose
 
Paul Ruff
Honoraria - Amgen; Sanofi
Research Funding - Multiple (Inst)
Travel, Accommodations, Expenses - Multiple
 
Attili Venkatasatya Suresh
No Relationships to Disclose
 
Anne L. Thomas
Speakers' Bureau - Roche Pharma AG
 
Sergei Tjulandin
Speakers' Bureau - AstraZeneca; Pfizer
 
Kathy Zhang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Roger Sidhu
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Swaminathan Murugappan
Employment - Amgen
Stock and Other Ownership Interests - Amgen